Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Choueiri, 2017, Systemic therapy for metastatic renal-cell carcinoma, N Engl J Med, 376, 354, 10.1056/NEJMra1601333 Motzer, 2008, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet (London, England), 372, 449, 10.1016/S0140-6736(08)61039-9 Motzer, 2009, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J Clin Oncol, 27, 3584, 10.1200/JCO.2008.20.1293 Motzer, 2013, Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial, Lancet Oncol, 14, 552, 10.1016/S1470-2045(13)70093-7 Choueiri, 2017, Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial, J Clin Oncol, 35, 591, 10.1200/JCO.2016.70.7398 Lambea, 2012, Quality of life and supportive care for patients with metastatic renal cell carcinoma, Cancer Metastasis Rev, 31, S33, 10.1007/s10555-012-9357-9 Tannir, 2018, Second-line treatment landscape for renal cell carcinoma: a comprehensive review, Oncologist, 23, 540, 10.1634/theoncologist.2017-0534 Motzer, 2017, Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma, J Clin Oncol, 35, 3916, 10.1200/JCO.2017.73.5324 Alsharedi, 2018, Check point inhibitors a new era in renal cell carcinoma treatment, Med Oncol, 35, 85, 10.1007/s12032-018-1147-y Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Motzer, 2015, Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial, J Clin Oncol, 33, 1430, 10.1200/JCO.2014.59.0703 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 de Velasco, 2019, Sequencing and combination of systemic therapy in metastatic renal cell carcinoma, Eur Urol Oncol, 2, 505, 10.1016/j.euo.2019.06.022 Rini, 2019, Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial, Lancet, 393, 2404, 10.1016/S0140-6736(19)30723-8 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1103, 10.1056/NEJMoa1816047 Albiges, 2015, Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma, Eur J Cancer, 51, 2580, 10.1016/j.ejca.2015.08.017 Shah, 2018, Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI), J Clin Oncol, 36, 682, 10.1200/JCO.2018.36.6_suppl.682 Auvray, 2019, Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma, Eur J Cancer, 108, 33, 10.1016/j.ejca.2018.11.031 Nadal, 2016, Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma, Ann Oncol, 27, 1304, 10.1093/annonc/mdw160 Heng, 2013, External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study, Lancet Oncol, 14, 141, 10.1016/S1470-2045(12)70559-4 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Barata, 2017, Treatment of renal cell carcinoma: Current status and future directions, CA Cancer J Clin, 67, 507, 10.3322/caac.21411 Iacovelli, 2015, Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma, Eur Urol, 68, 154, 10.1016/j.eururo.2014.10.034 Zarrabi, 2017, New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy, J Hematol Oncol, 10, 38, 10.1186/s13045-016-0374-y Choueiri, 2016, Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma, Clin Cancer Res, 22, 5461, 10.1158/1078-0432.CCR-15-2839 Dudani S, Graham J, Wells JC, et al. First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2019.07.048. Motzer, 2015, Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial, Lancet Oncol, 16, 1473, 10.1016/S1470-2045(15)00290-9 Leonetti, 2017, Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma, Ther Clin Risk Manage, 13, 799, 10.2147/TCRM.S126910 Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol, 27, 5794, 10.1200/JCO.2008.21.4809 Ko, 2015, The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study, Lancet Oncol, 16, 293, 10.1016/S1470-2045(14)71222-7 Wells, 2017, Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium, Eur Urol, 71, 204, 10.1016/j.eururo.2016.05.049 Powles, 2018, Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma, Br J Cancer, 119, 663, 10.1038/s41416-018-0164-0 McGregor, 2018, Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC), Ann Oncol, 29